Raghava R. Induru, MD
Molecular subtyping through next-generation sequencing has revolutionized the treatment paradigm of lung cancer diagnosis and treatment, according to Raghava R. Induru, MD.
OncLive: Please provide an overview of your presentation.
: The entire paradigm of treatment and testing in lung cancer has completely changed, and will continue to evolve over the next several years. From the common concept of lung cancer to molecular subtyping, the door has opened for newer and better treatments, which improve the quality of life of all patients with lung cancer.
We see [these advances] as a movement toward precision medicine, as we can subtype lung cancer as personalized as possible, and direct treatment accordingly. This will improve outcomes.
Let's zero in on BRAF. Can you discuss this mutation as a target?
BRAF is a well-known mutation in melanoma—that is where it first gained popularity—and V600E is the most common of that mutation found in lung cancer. It is found in about 3% of patients with NSCLC, and it is not exclusive to never-smokers, unlike what we see with EGFR
, and ROS1
mutations. Instead, this is found in smokers—over 60% of smokers could harbor this mutation. Which means the actual number of patients with lung cancer who have this mutation could be much higher than patients with ALK
... to read the full story